Does Erythropoietin Improve Outcome in Very Preterm Infants?
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main goal of this trial is to investigate whether early administration of human
erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months
corrected age.
This study is designed as randomized, double-masked, placebo controlled multicenter study
involving at least 420 patients.